Progression to AIDS in patients harboring human immunodeficiency virus type 1 (HIV -1) isolates expressing a syncytium-inducing (SI) phenotype is faster than in those in whom the virus expresses a non-SI (NSI) phenotype. Zidovudine monotherapy does not appear to alter this outcome. To examine the role of didanosine (ddl) monotherapy in phenotype expression, HIV-1 isolates from 73 patients receiving ddl for up to 72 weeks were analyzed. After 12 weeks, the number of isolates expressing an NSI phenotype was 29% higher than at the start of treatment. Patients receiving high-dose ddl (375 mg twice daily) were significantly more likely to express the NSI phenotype at 12 weeks than patients who received low-dose ddl (100 mg twice daily), even after adjustment for phenotype and CD4 cell count at baseline, suggesting that ddl may be selective against the fasterreplicating virus. ddl at 375 mg twice daily significantly increases the probability of an NSI phenotype over the short term in patients with advanced HIV disease.
Increasing emphasis is being placed on the biologic phenotype of human immunodeficiency virus (HIV) in the progression of AIDS [1] . Untreated persons who harbor high-replicating, syncytium-inducing (SI) virus variants or whose virus underwent a non-SI (NSI)-to-SI conversion have been reported to progress more rapidly to AIDS than those who persistently yielded NSI variants [2] [3] [4] . Independent studies [2, 5] of persons treated with zidovudine have shown that this drug does not prevent the emergence of SI variants, that patients with SI virus tend to have a poorer prognosis during zidovudine monotherapy, and that persons harboring SI virus have a greater chance of developing resistance to zidovudine.
Another nucleoside analogue with antiviral efficacy is didanosine (ddI). Patients who switch to ddI from zidovudine have an overall benefit in terms of disease progression [6] . As with zidovudine monotherapy, an SI variant and AIDS diagnosis prior to ddI therapy have been suggested to be poor prognostic factors [7] . The MRC/INSERM Alpha Trial, some results of which are reported here, was a randomized, double-blind trial of the efficacy and safety of high-dose (HD; 375 mg twice daily) versus low-dose (LD; 100 mg twice daily) ddI in persons infected with HIV-1 who were intolerant to zidovudine and had symptomatic HIV disease. This multicenter, multinational study began in 1990. At St. Vincent's Hospital, 175 participants were recruited.
Little information is available concerning the efficacy of ddI in persons with SI viruses. To ascertain the effect of ddI monotherapy on HIV-1 in vivo, we studied the in vitro biologic phenotype (SI or NSI) of virus isolates and evaluated the relationships between virus phenotype, CD4 cell count, and treatment with HD or LD ddI.
Methods and Materials
Trial regimen. Patients recruited into the Alpha trial had blood samples taken at baseline (week -2) and at weeks 12, 24, 48, and 72 after commencement of ddI therapy. Patients had received zidovudine for at least 6 months before ddI therapy. Blood samples at baseline formed the non-ddI-treated control group.
Viral culture. For each patient, at each time indicated, a sample of peripheral blood mononuclear cells (PBMC) was obtained. Patients' PBMC were separated from fresh whole blood by ficollhypaque (Amrad-Pharmacia Biotechnology, Uppsala, Sweden) gradient centrifugation. HIV-I was isolated from these cell fractions by a standard coculture technique [8] . Culture supernatant was collected every 3-4 days and stored at -70°C. p24 antigen assay (Coulter, Hialeah, FL) was used to determine virus concentration. A virus titer equivalent to a p24 level of >400 pg/mL was used as the inoculum to determine syncytium formation.
Syncytium formation. This was based on the method described by Tersmette et al. [9] , except that the MT-2 cell line was used. Cells (5 X 10 6 ) were inoculated with I mL of virus-containing culture supernatant and incubated for 2 h at 37°C. Syncytium formation was monitored daily for up to 30 days. Classification as SI required~10 syncytia per microscope field (X4). NOTE. SI, syncytium-inducing; NSI, non-SI.
Statistical analyses. CD4 cell count at baseline and change in CD4 cell count at week 12 from baseline were compared between phenotype and ddI dose groups using the Mann-Whitney and Kruskal-Wallis tests. The significance of phenotype at baseline, dose group, and CD4 cell count at baseline in predicting phenotype at week 12 was assessed using logistic regression analyses. Survival comparisons were done using a Cox model.
Results
SIINSI phenotyping was done on 235 virus isolates obtained from 76 patients who received ddl therapy for at least 12 weeks. Forty-two patients received LD and 34 received HD ddI. CD4 cell counts at baseline were unavailable for 3 patients. These patients were excluded, leaving 73 patients available for statistical analyses. Of the -2 week samples (table 1), 41 (56%) of 73 harbored NSI virus. After 12 weeks of ddl therapy, the proportion of isolates with an NSI phenotype had increased to 53 (73%) of 73. By week 12, phenotypes in 14 patients who had had an SI phenotype prior to ddl therapy changed to an NSI phenotype, 39 had remained NSI, 18 had remained SI, and 2 had switched from an NSI to an SI phenotype. After 12 weeks, the proportion of NSI virus gradually decreased (table  1) . By 72 weeks, 60 patients (82%) had withdrawn from the trial due to intolerance or death. For the patients whose phenotypes showed the SI-to-NSI reversion at 12 weeks, 8 maintained the NSI phenotype at 24 weeks, whereas 6 withdrew from therapy. Two patients continued to show the reversion at 48 weeks before withdrawing. Three patients showed an SI-to-NSI, then NSI-to-SI double reversion; 2 of these were detected at 48 weeks and the other at 72 weeks of therapy.
CD4 cell counts at baseline and the change in CD4 cell count at 12 weeks from baseline are summarized by phenotype and dose group in table 2. An SI phenotype at baseline was associated with a significantly lower CD4 cell count than an NSI phenotype (median, 17 vs. 46/J.LL; P = .02). For each of the 4 groups classified by SIINSI phenotype at baseline and week 12, the range of CD4 cell count was wide. With the exception of the SI-to-NSI group, all showed the proportion of patients whose CD4 cell count increased or decreased to be about the same. For the SI-to-NSI group, 80% showed a decrease in CD4 cell count (median change, -9 vs. 0/J.LL; P = .03).
Of the 14 patients whose phenotypes switched from SI to NSI between baseline and 12 weeks, 9 (640/0) were treated with HD and 5 (36%) with LD ddl. Furthermore, both patients whose phenotypes switched from NSI to SI received LD ddl. Patients who received HD ddl were significantly more likely to have an NSI phenotype at 12 weeks than patients who received LD ddl, even after adjustment for phenotype and CD4 cell count at baseline (odds ratio, 5.5; P = .02; table 3).
Comparison of the survival between patients who had an SI phenotype at baseline that remained at 12 weeks (SI-SI) and those who had the SI-to-NSI change between baseline and 12 weeks showed no statistically significant difference (risk of death, SI-to-NSI vs. SI-SI group, 1.45; 95% confidence interval, 0.69-3.06; P = .3; table 4). This comparison, however, was based on small numbers. Phenotype and CD4 cell count at baseline were predictive of overall survival (table 4), but the ddl dose was not predictive of outcome, even though the SI-to-NSI switch was more closely associated with an HD regimen.
Discussion
We investigated the pattern of development of SI and NSI phenotypes in HIV isolates from 73 patients switched to ddl monotherapy because of intolerance to zidovudine after they had received zidovudine for at least 6 months. Patients were followed for up to 72 weeks of therapy. ddl had a significant impact on suppression of the fast-replicating SI phenotype. Ultimately, this could lead to reduced or delayed selection of ddl-resistant variants. This, together with the observations of early (within 4 weeks of therapy) and prolonged decreases (60%-98%) in viral replication and virus load for patients enrolled in the Alpha trial reported by others [10] , indicates that an SI phenotype could also prove to be useful as a prognostic marker.
Our investigation also showed that only 44% of the patients entering the trial harbored SI virus. This is despite the advanced disease stage (AIDS-related complex or AIDS) and low CD4 cell counts of these patients. This proportion compares with the result «50%) of Jurriaans et al. [11] but is lower than that (67%) reported by Japour et al. [12] . The data presented here suggest that a higher CD4 cell count and a virus isolate with an NSI phenotype at baseline were significant characteristics for maintaining the expression of this phenotype during the early stages of ddl therapy. This result is consistent with the report of Richman and Bozzette [13] , which showed that the presence of an SI phenotype was a strong predictor of a decline in CD4 cell count.
Patients with an SI virus have been shown to be more likely to have a diagnosis of AIDS, detectable serum p24, a lower CD4 cell count, and a higher level of ,82-microglobulin [14] . Viruses expressing the SI phenotype have accelerated rates of replication [15] [16] [17] [18] . The phenotypic switch from a predominantly quickly replicating (SI) to slowly replicating (NSI) popu- lation after 12 weeks of therapy and its association with HD ddI indicate a selection against the more aggressive form. This finding may be important for the design of future drug protocols. Changes in the amino acid composition of the VI, V2, and V3 hypervariable loops of gp120 are known to be involved in determining SIINSI phenotype. Changes at positions 11 and 25 of V3 have been associated with an SI phenotype [19, 20] .
According to Fouchier et al. [21] , a change (either singly or in combination) to a basic amino acid at these positions would result in a higher probability of the isolates being SI. If the amino acid at position 11 is uncharged and that at position 25 is uncharged or acidic, the virus isolates are NSI. Another study suggested that a negatively charged amino acid at residue 25 was associated with an NSI phenotype [22] . The V2 domain has also been shown to contain a major determinant of SI NOTE. SI, SYncytium-inducing; NSI, non-Sl; RR, relative risk; CI, confit CD4 count at baseline is adjusted for phenotype at baseline and dose level, dence interval. which are adjusted for each other.
* Survival comparisons by Cox model. capacity, the configuration of which is also predictive for an NSI-to-SI phenotype conversion [23, 24] . As reported by Freed and Martin [25] , the VI and V2 regions can influence the extent of syncytium formation, perhaps through a functional interaction with the C4 region ofgpl20. Therefore, the possibility exists that the observed SI-to-NSI reversion was due to specific changes in the VI, V2, and V3 loops. These explanations may be related. If ddl selects against the more aggressive SI virus, as suggested by the SI-to-NSI reversion, then it may indirectly select for the amino acid changes indicated that confer an NSI phenotype. If 'ddl were equally effective against both SI and NSI virus, the overall phenotype would not be expected to change. The syncytium formation assay allows for the detection of as little as 5% of virus with an SI phenotype in an NSI virus background [26] . This suggests that in the clinical situation, ddl successfully altered the population dynamics of HIV in some patients, resulting in a background SI population of < 5°Al.
However, this did not alter the risk of progression. Unfortunately the syncytium formation assay is only qualitative. To determine how successfully ddl reduced the SI population would require a quantitative assay, which is unavailable at present. . The disappearance of an SI strain and the appearance of NSI strains in sequential isolates from patients treated with ddl has recently been reported by Delforge et al. [27] . This feature was transient and occurred between 5 and 8 months of ddl therapy, rather later than observed in our study. The SI-to-NSI reversion during ddI therapy we observed highlights the importance of including an SI assay as an independent factor for determining the risk of progression to AIDS. Unfortunately, most of the patients studied demonstrated rapid decline in clinical and biologic parameters after 12 weeks of ddI treatment. Further studies comparing the genetic background of the reverse transcriptase region of these HIV-1 isolates are in progress to enable correlation with the SIINSI phenotype.
The SI-to-NSI switch was also associated with an overall decrease in CD4 cell number. However, it should be noted that the comparison of CD4 cell count change between the SI-to-NSI and SI-SI groups (P = .03) was only just significant.
Overall, there was no significant difference between all 4 groups (table 2), so this decrease in CD4 cell count could be a chance observation.
In a study by Karlsson et al. [28] , 2 (12%) of 16 patients whose virus changed from an NSI to an SI phenotype showed a stable or increasing CD4 cell number. Usually NSI-to-SI changes are associated with a decrease in CD4 cell number [14] . Our observation of an SI-to-NSI change with an overall decrease in CD4 cell count for 12 of 14 patients further illustrates the broad spectrum of events surrounding the biologic phenotype described by Karlsson et al. [28] that occur during changes in tropism.
It is also important to note that the retrospective nature of our virologic substudy, the lack of an ideal control group, and the relatively small numbers make most of the clinical and immunologic observations less than definitive. The true relevance of our findings will need to be answered by larger, prospective trials that further explore these important observations.
Anti-HIV-1 agents investigated as monotherapy result in only a partial suppression of viral replication and ddl is no exception. Because the benefits observed with monotherapy do not result in a long-lasting reduction in virus load or viral replication rates, combination trials are being investigated. The results obtained from recently completed monotherapy trials, such as Alpha, may provide further recommendations allowing for more effective drug use in combination.
